FRX Forest Road Acquisition Corp

Forest Laboratories Revises FY2005 Earnings Guidance NEW YORK, Nov. 1 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) announced today that following the October 28th Food and Drug Administration approval and subsequent launch of several generic versions of its branded SSRI antidepressant Celexa(R), including a launch by Forest's generic division, Inwood Laboratories, it has revised its guidance for diluted earnings per share for the fiscal year ending March 31, 2005. Forest currently expects that diluted earnings per share for fiscal 2005 will be approximately $2.50 compared to reported diluted earnings per share in fiscal 2004 of $1.95. This guidance allows for marketing expenses associated with the launch of Campral(R) for alcohol dependence and the potential launch of Combunox(TM) for the management of acute, moderate to severe pain in the fiscal fourth quarter. The Company does not expect to make any operational changes as a result of the launch of generic versions of Celexa, nor will there be any impact on its gross margins. (Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements are subject to risks and uncertainties that affect our business, including risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2004 and the quarterly report on Form 10-Q for the period ended June 30, 2004. Actual results may differ materially from those projected. http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGODATASOURCE: Forest Laboratories, Inc. CONTACT: CHARLES E. TRIANO, Vice President - Investor Relations of Forest Laboratories, Inc., +1-212-224-6714, Web site: http://www.frx.com/

Copyright